Remetinostat

Description: Remetinostat (formerly known as SHP-141) is an inhibitor of histone deacetylase (HDAC) developed by Medivir as a topical application for use in early stage CTCL (Cutaneous T-cell lymphoma). HDAC inhibitors are approved for treatment of CTCL in late-stage patients but are not recommended for early-stage patients due to their significant side effects. The unique design of remetinostat enables topical application, making it active only in the skin. As soon as it reaches the blood stream, it is degraded, avoiding the side effects associated with other HDAC inhibitors. In the phase II study, remetinostat demonstrated efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage CTCL.

References: http://www.medivir.com/our-projects/proprietary/remetinostat